DOCSLIB.ORG

Randall C. Starling, M.D., M.P.H., F.A.C.C., F.A.H.A.,F.E.S.C., F.H.F.S.A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Randall C. Starling, M.D., M.P.H., F.A.C.C., F.A.H.A.,F.E.S.C., F.H.F.S.A CURRICULUM VITAE RANDALL C. STARLING, M.D., M.P.H., F.A.C.C., F.A.H.A.,F.E.S.C., F.H.F.S.A. FEBRUARY 2019 PERSONAL INFORMATION Name: Starling, Randall Carson Place of Birth: Pittsburgh, Pennsylvania, USA Citizenship: United States of America Education University of Pittsburgh Pittsburgh, Pennsylvania B.S. Biology, Cum Laude 1969 – 1973 University of Pittsburgh, School of Public Health Pittsburgh, Pennsylvania M.P.H., Summa Cum Laude 1974 – 1975 Temple University School of Medicine Philadelphia, Pennsylvania M.D., Honor Graduate 1977 – 1981 Post-Graduate Training The Ohio State University Division of Cardiology Columbus, Ohio Director: Carl V. Leier, M.D. Cardiology Fellowship 1985 – 1987 University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania Director: Gerald S. Levey, M.D. Chief Medical Resident Instructor in Medicine 1984 – 1985 University of Pittsburgh Medical Center Pittsburgh, Pennsylvania Director: Gerald S. Levey, M.D. Internal Medicine Residency 1982 - 1984 University of Pittsburgh Medical Center Pittsburgh, Pennsylvania Director: Gerald S. Levey, M.D. Internal Medicine Internship 1981 - 1982 Contact Information Office Address: Cleveland Clinic Department of Cardiovascular Medicine Section of Heart Failure and Transplant Medicine 9500 Euclid Avenue / J3-4 Cleveland, Ohio 44195 Office Phone: (216) 444-2268 Facsimile: (216) 636-6974 E-mail: [email protected] Home Address: 513 Fawn Court Chagrin Falls, Ohio 44022 Home Phone: (440) 338-4301 PROFESSIONAL APPOINTMENTS Member, Board of Trustees Cleveland Clinic Cleveland, OH 2013-2014 Interim Chairman, Department of Cardiovascular Medicine Cleveland Clinic Florida Weston, Florida February 2011 – November 2012 Member, Board of Governors 5 Year Term Cleveland Clinic Cleveland, Ohio 2010 – 2015 Vice Chairman, Department of Cardiovascular Medicine Cleveland Clinic Cleveland, OH 2006 – 2016 Professor of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland, Ohio 2006 – Present Head, Section of Heart Failure and Cardiac Transplant Medicine Cleveland Clinic Department of Cardiovascular Medicine Cleveland, Ohio November 2003 – January 2016 Medical Director, Heart Transplant Program UNOS Lead Physician Cleveland Clinic Heart Transplant Program January 2004 – March 2019 2 Randall C. Starling, MD, MPH, FACC, FESC, FHFSA Medical Director, Kaufman Center for Heart Failure Cleveland Clinic Cleveland, Ohio 2003 – January 2016 Joint Appointment Staff Physician Cleveland Clinic Multi-Organ Transplant Center Cleveland, Ohio 1998 – Present Program Director Advanced Fellowship in Heart Failure and Cardiac Transplant Medicine Fellowship Cleveland Clinic 1995 – 2003 Staff Physician Director, Heart Transplant Medical Services Cleveland Clinic Department of Cardiovascular Medicine Cleveland, Ohio 1995 – 2003 Associate Professor of Medicine, with Tenure Medical Director, Cardiac Transplant Program Director, Endomyocardial Biopsy Lab The Ohio State University Division of Cardiology Columbus, Ohio 1994 – 1995 Assistant Professor of Medicine Medical Director, Cardiac Transplant Program Director, Endomyocardial Biopsy Lab The Ohio State University Division of Cardiology Columbus, Ohio 1992 – 1994 Assistant Professor of Medicine Medical Director, Cardiac Transplant Program University of Pittsburgh Medical Center Pittsburgh, Pennsylvania 1991 – 1992 Adjunct Assistant Professor of Medicine The Ohio State University Division of Cardiology Columbus, Ohio 1991 – 1992 Assistant Professor of Medicine The Ohio State University Division of Cardiology Columbus, Ohio 1988 – 1991 3 Randall C. Starling, MD, MPH, FACC, FESC, FHFSA Clinical Assistant Professor of Medicine The Ohio State University Division of Cardiology Columbus, Ohio 1987 – 1988 CERTIFICATION AND LICENSURE 2010 Florida (ME 107791) 2003 Massachusetts (218951) 2003 Michigan (4301082516) 2003 New York (230137) 1986 Ohio (35-053357) 1982 Pennsylvania (MD027607E) 2010 American Board of Internal Medicine Advanced Heat Failure/Transplant Cardiology Certified 11/08/2010 - 12/31/2020 2010 Re certified, Diplomat in Internal Medicine (97797) American Board of Internal Medicine (97797) 1989 Diplomat in the Subspecialty of Cardiovascular Disease, American Board of Internal Medicine (97797) 1984 Diplomat in Internal Medicine, American Board of Internal Medicine (97797) 1982 National Board of Medical Examiners (254215) HONORS AND AWARDS Fellowship of the Heart Failure Society of America (Inaugural Group) - 2016 Temple University, Medical Alumni Achievement Award – 2016 Best Doctors in America, 2002, 2004-2015 Best Doctors in America, Midwest Region, 1996 National Institutes of Health Research Apprenticeship Program, The Ohio State University College of Medicine, 1993 Mosby Book Scholarship Award, 1981 Alpha Omega Alpha, Temple University School of Medicine, 1980 MEMBERSHIP IN PROFESSIONAL SOCIETIES American College of Cardiology, Fellow American Heart Association Council on Clinical Cardiology, Member, Fellow American Society of Transplantation, Member inactive Heart Failure Society of America, Member and Fellow Heart Failure Association of the European Society of Cardiology, Member, Fellow The European Society of Cardiology, Fellow The International Society for Heart and Lung Transplantation, Member PROFESSIONAL SERVICES 4 Randall C. Starling, MD, MPH, FACC, FESC, FHFSA Editorial Boards: Journal of the American College of Cardiology: Past member editorial board, current ad hoc reviewer JACC Heart Failure: Editorial Consultant 2011 – present Heart Failure Reviews: Editorial Board. 2016—2018 Associate Editor 2018- present Circulation, 2016 – present Journal of Heart and Lung Transplantation: Past member editorial board, current ad hoc reviewer Greek Journal of Heart Failure: International Editor in Chief New England Journal of Medicine, Lancet, JAMA: Ad hoc reviewer COMMITTEE SERVICE National: American Board of Internal Medicine, Heart Failure and Transplant Committee, ad hoc member. November 2016. Heart Failure Society of America, President, 2018 – 2019. Heart Failure Society of America, Treasurer and member Strategic Planning Committee, 2016 – 2017. 2016 ACC/AHA/HFSA Focused Update on New Pharmacologic Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guidelines for the Management of Heart Failure – Peer Reviewer, April 2016 ACC Appropriateness Use Committee, Cardiovascular Imaging Committee Member, Denver, CO. September 2016. ACC/AATS/AHA/ASE/ASNC/HFSA/HRS/SCAI/ SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in Cardiovascular Evaluation of Patients Undergoing Non-Emergent, Non-Cardiac Surgery 2018-ongoing American College of Cardiology Program Committee, Member, 2016 – 2019 American College of Cardiology, Committee Member Heart Failure and Transplant 2016-2019 American Medical Group Association, Member Heart Failure Collaborative. 2015 – 2017. Arlington, VA. Heart Failure Society of American, Member, Finance Committee, Chevy Chase, MD, 2015 - 2018 Heart Transplant Representative to United Network for Organ Sharing (UNOS) Board of Directors, OPTN Board of Directors, June 2010 – June 2012 Heart Failure Society of America, Member, Program Committee, Minneapolis, Minnesota, 2010 – 2011 International Society for Heart and Lung Transplantation, 30th Annual Meeting and Scientific Sessions, Program Committee, Chicago, Illinois, April 21-24, 2010 Heart Mate II Clinical Trial, Member, Publication Committee, February 2010 Heart Failure Society of America, Abstract Reviewer, 2010 5 Randall C. Starling, MD, MPH, FACC, FESC, FHFSA Thoratec Corporation, Member, Publication Committee, HeartMate II Clinical Trial, Pleasanton, California, 2010 Member, American Board of Internal Medicine, ABIM Test Committee on Advanced Heart Failure and Transplant Cardiology, July 1, 2009 – June 30, 2015 Cleveland Clinic Heart and Vascular Institute Comprehensive International Symposium, The Treatment of Cardiovascular Disease: Legacy and Innovation, Program Committee, Cleveland, Ohio, June 3-5, 2009 International Society for Heart and Lung Transplantation, 29th Annual Meeting and Scientific Sessions, Program Chairman, Paris, France, April 22-25, 2009 Heart Failure Society of America, Member, Executive Council, Minneapolis, Minnesota, 2008 – 2014 Abstract Reviewer, International Society for Heart and Lung Transplantation, 2007, 2010, 2011 International Society of Heart and Lung Transplantation, Member, Board of Directors, Dallas, Texas 2006-2009 Annual Scientific Sessions, American College of Cardiology, Co-Chair, Program Committee, 2006 – 2008 Organ Procurement and Transplantation Network / United Network for Organ Sharing, Membership and Professional Standards Committee AND Policy Compliance Subcommittee, 2006 – 2008 Medtronic, Incorporated, Cardiac Rhythm Disease Management Division, Advisor, Co- Management Council of Advisors, Minneapolis, Minnesota, March 2006 – present. AHA/ACC/ESC Scientific Statement Writing Group, The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease, Member, 2006 World Heart Incorporated, Executive Committee, RELIANT Trial, 2006 Arrow International, Member, Clinical Events Review Committee for European Cor Aide Trial, Wyomissing, Pennsylvania, 2005 – Present WellPoint, Incorporated, Member, National Transplant Quality Review Committee, Denver, Colorado, 2005-Present American College of Cardiology, Abstract Reviewer, 2005-2008, 2012-2016. Annual Scientific Sessions, American College of Cardiology, Program Committee, 2005 – 2008 Heart Failure Society of America,
Load more

Recommended publications
  • A Single Center's Experience with Total Arterial Revascularization and Spiral
    Heart and Vessels (2019) 34:906–915 https://doi.org/10.1007/s00380-018-1317-z ORIGINAL ARTICLE A single center’s experience with total arterial revascularization and spiral aneurysmorrhaphy for ischemic cardiac disease Ilias P. Doulamis1 · Despina N. Perrea1 · George Mastrokostopoulos2 · Konstantina Drakopoulou2 · Konstantinos Voutetakis3 · Aspasia Tzani1 · Ioannis A. Chloroyiannis3 Received: 5 September 2018 / Accepted: 30 November 2018 / Published online: 6 December 2018 © Springer Japan KK, part of Springer Nature 2018 Abstract The restoration of left ventricular (LV) geometry in combination with coronary artery bypass grafting for the treatment of ischemic cardiac disease remains controversial. We hereby present the experience of our center with total arterial myocar- dial revascularization (TAMR) and spiral aneurysmorrhaphy for ischemic heart disease. A retrospective analysis of 101 patients with advanced cardiovascular disease who underwent TAMR and spiral aneurysmorrhaphy was performed. Spiral aneurysmorrhaphy is a modifcation of the linear aneurysmorrhaphy and was applied to patients who had a LV aneurysm with a diameter of less than 5 cm. Peri-operative and in-hospital data were retrieved. The majority of the patients were male (87.13%) with a mean age of 63.1 years. Mean pre-operative ejection fraction (EF) was 35.7% ranging between 20 and 65%. An average of 3.23 grafts was required per patient. Early mortality was 6.93% (one intra-operative and six in-hospital deaths). Addition of concomitant valve surgery was associated with prolonged total operative, cardiopulmonary bypass and cross-clamp time (p < 0.001), increased need for blood (p = 0.012) and plasma (p = 0.038), longer intensive care unit (ICU) stay (p = 0.045) and higher rate of post-operative cerebrovascular accident (p = 0.011).
    [Show full text]
  • Curriculum Vitae Takahiro Shiota, MD, Phd, FACC, FESC, FASE, FAHA
    1 Curriculum Vitae Takahiro Shiota, MD, PhD, FACC, FESC, FASE, FAHA Office Address: Cedars-Sinai Medical Center Heart Institute 127 S. San Vicente Blvd., A3411 Los Angeles, CA 90048 (310) 423-6889 Office Email: [email protected] EDUCATION: 1991 Ph.D. in Cardiology. Faculty of Medicine, University of Tokyo, Tokyo, Japan 1977-1983 M.D. Faculty of Medicine, University of Tokyo, Tokyo, Japan 1972-1976 B.S. in Physics. Faculty of Science, University of Tokyo, Tokyo, Japan LICENSURE AND CERTIFICATION National Board of Echocardiography (#2000-252) California Medical License (#000015) Ohio Medical License (#35. 080318) ECFMG (#0-576-045-9) Japanese Medical License (#274951) PROFESSIONAL EXPERIENCE 1/2009-present Associate Director Division of Noninvasive Cardiology Cedars-Sinai Heart Institute Los Angeles, CA 12/2001-12/2008 Clinical Staff Department of Cardiovascular Medicine Cleveland Clinic, Cleveland, OH 7/1999-11/2001 Advanced Cardiac Department of Cardiovascular Medicine Imaging Fellow Cleveland Clinic, Cleveland, OH 9/1997- 6/1999 Project Staff Department of Cardiovascular Medicine 2 Cleveland Clinic, Cleveland, OH 8/1992- 8/1997 Research Director Cardiac Imaging Laboratory, Clinical Care Center for Congenital Heart Disease, Oregon Health Sciences University, Portland, OR PROFESSIONAL ACTIVITIES: Academic Appointment 7/2009-present Professor of Medicine, Department of Medicine, Cedars-Sinai, Los Angeles, CA 8/2008-present Clinical Professor of Medicine, David Geffen School of Medicine at UCLA 7/2007-12/2008 Professor of Medicine, Cleveland
    [Show full text]
  • Surgical Ventricular Restoration for Post Infarction Left Ventricular Aneurysm
    Medical Group International Journal of Vascular Surgery and Medicine ISSN: 2455-5452 DOI CC By JR Vijay Kumar, HS Natraj Setty*, Case Report Rajiv Ananthakrishna, Rahul Patil, Seetharama PS Bhat and CN Surgical Ventricular Restoration Manjunath Sri Jayadeva Institute of Cardiovascular Sciences for Post infarction Left Ventricular and Research, Bengaluru, Karnataka, India Dates: Received: 01 January, 2017; Accepted: 21 Aneurysm February, 2017; Published: 24 February, 2017 *Corresponding author: Natraj Setty HS, Doctor, Sri Jayadeva Institute of Cardiovascular Sciences and Abstract Research Bangalore, #493, 4th Cross, 7th Main, JP. Nagar, 3rd Phase, Bangalore – 69, Karnataka, India, Tel: Surgical ventricular restoration is a procedure designed to restore or remodel the left ventricle. Surgical + 9845612322;+ 080-26580051; Fax: + 080-22977261; ventricular restoration by means of the Dor procedure is a surgical option in patients with coronary artery E-Mail: disease, postinfarction left ventricular aneurysm (LV aneurysm) or ischemic dilated cardiomyopathy Keywords: Left ventricular aneurys; Dor procedure; with or without ventricular tachycardia. Postinfarction left ventricular remodeling is characterized by 2D Echo LV dilatation and abnormal geometry leading to systolic and diastolic dysfunction. Development of a left ventricular aneurysm is a serious long-term complication of Acute Myocardial Infarction. We report https://www.peertechz.com a 69 year old male presented with haemodynamically signifi cant ventricular tachycardia, successfully underwent DOR Procedure with complete recovery. Case Profi le by Dor and colleagues [3]. Was introduced to improve geometric reconstruction with respect to standard linear repair in Left A 69 year- old- male, presented with hemodynamically ventricle aneurysm. Subsequently, Dor and colleagues [4]. signifi cant ventricular tachycardia.
    [Show full text]
  • An Extensive Calcified Left Ventricular Aneurysm: Case Report
    OLGU SUNUMU An Extensive Calcified Left Ventricular Aneurysm: Case Report İhsan ALUR, a ABSTRACT A calcified left ventricular aneurysm (CLVA) is a rare, serious complication of acute Tevfik GÜNEŞ, a myocardial infarction. It can lead to angina pectoris, thromboembolism of ventricular origin, ven - a tricular arrhythmia, ventricular pseudoaneurysm or rupture, progressively enlarging aneurysms, Gökhan Yiğit TANRISEVER, congestive heart failure, and death. Treatment is surgical for symptomatic or asymptomatic LVAs a Bilgin EMRECAN larger than 5 cm, particularly when there is comorbid coronay artery disease. Its standard treatment is a ventriculoplasty and aneurysmectomy using the Dor technique. The aim of surgical treatment aDepartment of Cardiovascular Surgery, of an LVA is to reduce oxygen consumption in the LV by reducing end-diastolic volume (EDV), cre - Pamukkale University ating the ideal ventricle geometry, and preventing thrombus formation. The surgical results are Faculty of Medicine, Denizli often good. This article presents a patient with CLVA in whom we performed surgery. Ge liş Ta ri hi/ Re ce i ved: 12.02.2016 Key Words: Heart ventricles; heart aneurysm; thoracic surgery Ka bul Ta ri hi/ Ac cep ted: 04.04.2016 ÖZET Kalsifik sol ventrikül anevrizması (KSVA) akut miyokard infarktüsünün nadir ve ciddi bir Ya zış ma Ad re si/ Cor res pon den ce: komplikasyonudur. Bu komplikasyon anjina pektoris, ventriküler kaynaklı tromboemboli, ventri - İhsan ALUR küler aritmi, ventriküler psödoanevrizma veya rüptür, progresif genişleyen anevrizma ve konjestif Pamukkale University kalp yetersizliği gibi fatal kardiyak olaylara yol açabilir. Semptomatik veya asemptomatik, 5 cm’den Faculty of Medicine, büyük SVA’ların, özellikle eşlik eden koroner arter hastalığı da varsa tedavisi cerrahidir.
    [Show full text]
  • The Memory of the Heart
    Journal of Cardiovascular Development and Disease Review The Memory of the Heart Marco Cirillo Heart Failure Surgery Unit, Cardiac Surgery Unit, Cardiovascular Department, Poliambulanza Foundation Hospital, Via Leonida Bissolati 57, 25125 Brescia, Italy; [email protected]; Tel.: +39-030-351-8088 Received: 2 October 2018; Accepted: 8 November 2018; Published: 11 November 2018 Abstract: The embryological development of the heart is one of the most fascinating phenomena in nature and so is its final structure and function. The various ontogenetic passages form the evolutive basis of the final configuration of the heart. Each key step can be recognized in the final features, as the heart maintains a kind of “memory” of these passages. We can identify the major lines of development of the heart and trace these lines up to the mature organ. The aim of this review is to identify these key parameters of cardiac structure and function as essential elements of the heart’s proper functioning and bases for its treatment. We aim to track key steps of heart development to identify what it “remembers” and maintains in its final form as positively selected. A new vision based on the whole acquired knowledge must guide an in-depth scientific approach in future papers and guidelines on the topic and a complete, farsighted therapeutic conduct able to ensure the physiological correction of cardiac pathologies. The application of this modern, functional vision of the heart could improve the clinical treatment of heart disease, filling the gaps still present. Keywords: heart embryology; myocardial structure; interlaced myocardial fibers; cardiomyopathy; left ventricular reconstruction; heart failure; valve disease; mitral regurgitation; guidelines; cardiac resynchronization 1.
    [Show full text]
  • Surgical Ventricular Restoration
    Surgical Ventricular Restoration Policy # 00184 Original Effective Date: 01/26/2006 Current Effective Date: 06/14/2021 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically. Services Are Considered Investigational Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products. Based on review of available data the Company considers surgical ventricular restoration (SVR) for the treatment of ischemic dilated cardiomyopathy to be investigational.* Policy Guidelines Surgical ventricular restoration involves increased physician work compared with standard ventriculectomy. For example, the procedure includes evaluation of the ventricular septum and reshaping of the geometry of the heart. Surgical ventricular restoration is described as a global treatment of left ventricular failure, while conventional left ventricular aneurysmectomy represents a local treatment of a transmural infarct. Background/Overview Surgical ventricular restoration is also known as surgical anterior ventricular endocardial restoration, left ventricular reconstructive surgery, endoventricular circular plasty, or the Dor procedure. Named after the surgeon who pioneered the expansion of techniques for ventricular reconstruction and is credited with treating heart failure patients with SVR and coronary artery bypass grafting. SVR is usually performed after coronary artery bypass grafting and may precede or be followed by mitral valve repair or replacement and other procedures such as endocardectomy and cryoablation for treatment of ventricular tachycardia. A key difference between SVR and ventriculectomy (ie, for aneurysm removal) is that, in SVR, circular “purse string” suturing is used around the border of the aneurysmal scar tissue.
    [Show full text]
  • Medical Policy Surgical Ventricular Restoration
    Medical Policy Surgical Ventricular Restoration Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization Information Policy History Policy Number: 544 BCBSA Reference Number: 7.01.103 Related Policies None Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Surgical ventricular restoration is INVESTIGATIONAL for the treatment of ischemic dilated cardiomyopathy or post-infarction left ventricular aneurysm. Prior Authorization Information Commercial Members: Managed Care (HMO and POS) This is NOT a covered service. Commercial Members: PPO, and Indemnity This is NOT a covered service. Medicare Members: HMO BlueSM This is NOT a covered service. Medicare Members: PPO BlueSM This is NOT a covered service. CPT Codes / HCPCS Codes / ICD-9 Codes The following codes are included below for informational purposes. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member. A draft of future ICD-10 Coding related to this document, as it might look today, is included below for your reference. 1 Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable. CPT Codes CPT codes: Code Description
    [Show full text]
  • Surgical Treatment of Heart Failure
    MEDICAL POLICY POLICY TITLE SURGICAL TREATMENT OF HEART FAILURE POLICY NUMBER MP-1.082 Original Issue Date (Created): 8/23/2002 Most Recent Review Date (Revised): 4/22/2021 Effective Date: 9/1/2021 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY I. POLICY Partial Left Ventriculectomy Partial left ventriculectomy is considered not medically necessary. Surgical Ventricular Restoration Surgical ventricular restoration is considered investigational for the treatment of ischemic dilated cardiomyopathy or post-infarction left ventricular aneurysm, as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure. Cross-reference: MP-1.026 Total Artificial Hearts and Implantable Ventricular Assist Devices II. PRODUCT VARIATIONS Top This policy is only applicable to certain programs and products administered by Capital BlueCross please see additional information below, and subject to benefit variations as discussed in Section VI below. FEP PPO: Refer to FEP Benefit Brochure for information on Surgical treatment of heart failure: https://www.fepblue.org/benefit-plans/benefit-plans-brochures-and-forms Note* - The Federal Employee Program (FEP) Service Benefit Plan does not have a medical policy related to these services. Page 1 MEDICAL POLICY POLICY TITLE SURGICAL TREATMENT OF HEART FAILURE POLICY NUMBER MP-1.082 III. DESCRIPTION/BACKGROUND Top Partial Left Ventriculectomy Partial left ventriculectomy (PLV) is a surgical procedure aimed at improving the hemodynamic status of patients with end-stage congestive heart failure (CHF) by directly reducing left ventricular size, and thereby improving the pump function of the left ventricle (LV). This surgical approach to the treatment of congestive heart failure (CHF) (also known as the Batista procedure, cardio-reduction, or left ventricular remodeling surgery) is primarily directed at patients with an underlying non-ischemic dilated cardiomyopathy.
    [Show full text]
  • 398955542006.Pdf
    Brazilian Journal of Cardiovascular Surgery ISSN: 0102-7638 ISSN: 1678-9741 Sociedade Brasileira de Cirurgia Cardiovascular Kaya, Ugur; Çolak, Abdurrahim; Becit, Necip; Ceviz, Munacettin; Kocak, Hikmet Application of Circular Patch Plasty (Dor Procedure) or Linear Repair Techniques in the Treatment of Left Ventricular Aneurysms Brazilian Journal of Cardiovascular Surgery, vol. 33, no. 2, 2018, March-April, pp. 135-142 Sociedade Brasileira de Cirurgia Cardiovascular DOI: 10.21470/1678-9741-2017-0093 Available in: http://www.redalyc.org/articulo.oa?id=398955542006 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative ORIGINAL ARTICLE Braz J Cardiovasc Surg 2018;33(2):135-42 Application of Circular Patch Plasty (Dor Procedure) or Linear Repair Techniques in the Treatment of Left Ventricular Aneurysms Ugur Kaya1, MD; Abdurrahim Çolak1, MD; Necip Becit1, MD; Munacettin Ceviz1, MD; Hikmet Kocak1, MD DOI: 10.21470/1678-9741-2017-0093 Abstract anterior descending (LAD) disease in 34 (38.2%) patients were Objective: The aim of this study was to evaluate early clinical identified. Five (5.6%) patients underwent aneurysmectomy outcomes and echocardiographic measurements of the left alone, while the remaining 84 (94.3%) patients had ventricle in patients who underwent left ventricular aneurysm aneurysmectomy with bypass. The mean number of grafts per repair using two different techniques associated to myocardial patient was 2.1±1.2 with the Dor procedure and 2.9±1.3 with the revascularization.
    [Show full text]
  • (Dor Procedure) Or Linear Repair Techniques in the Treatment of Left Ventricular Aneurysms
    ORIGINAL ARTICLE Braz J Cardiovasc Surg 2018;33(2):135-42 Application of Circular Patch Plasty (Dor Procedure) or Linear Repair Techniques in the Treatment of Left Ventricular Aneurysms Ugur Kaya1, MD; Abdurrahim Çolak1, MD; Necip Becit1, MD; Munacettin Ceviz1, MD; Hikmet Kocak1, MD DOI: 10.21470/1678-9741-2017-0093 Abstract anterior descending (LAD) disease in 34 (38.2%) patients were Objective: The aim of this study was to evaluate early clinical identified. Five (5.6%) patients underwent aneurysmectomy outcomes and echocardiographic measurements of the left alone, while the remaining 84 (94.3%) patients had ventricle in patients who underwent left ventricular aneurysm aneurysmectomy with bypass. The mean number of grafts per repair using two different techniques associated to myocardial patient was 2.1±1.2 with the Dor procedure and 2.9±1.3 with the revascularization. linear repair technique. In-hospital mortality occurred in 4.1% Methods: Eighty-nine patients (74 males, 15 females; mean and 7.3% in group A and group B, respectively (P>0.05). age 58±8.4 years; range: 41 to 80 years) underwent post- Conclusion: The results of our study demonstrate that post- infarction left ventricular aneurysm repair and myocardial infarction left ventricular aneurysm repair can be performed revascularization performed between 1996 and 2016. Ventricular with both techniques with acceptable surgical risk and with reconstruction was performed using endoventricular circular satisfactory hemodynamic improvement. patch plasty (Dor procedure) (n=48; group A) or linear repair Keywords: Heart Ventricles/Surgery. Heart Aneurysm. technique (n=41; group B). Myocardial Revascularization. Coronary Artery Bypass. Cardiac Results: Multi-vessel disease in 55 (61.7%) and isolated left Surgical Procedures/Methods.
    [Show full text]
  • Surgical Treatment of Ischemic Heart Failure the Dor Procedure
    REVIEW Cardiovascular Surgery Circ J 2009; Suppl A: A-1 – A-5 Surgical Treatment of Ischemic Heart Failure The Dor Procedure Marisa Di Donato, MD*,**; Serenella Castelvecchio, MD*; Lorenzo Menicanti, MD* Despite the improvements in the treatment of myocardial infarction that have translated into a decline in mortality rates, the incidence of heart failure has increased and, because of the limited number of cardiac donors, non- transplant heart surgery has developed in the past 10 years. Surgical ventricular reconstruction was launched by Dor and defined as endoventricular circular patch plasty repair. It represents a relatively novel surgical approach aiming to restore (bring back to normal) the dilated, distorted left ventricular (LV) cavity in order to improve function. The term ‘surgical ventricular reconstruction/restoration’ includes operative methods that reduce LV volume and restore its shape. The concept of reducing wall stress through surgical restoration of chamber size and geometry remains the guiding principle behind this innovative technique. Results from different Institutions are uniform and show an improvement in cardiac and clinical status and in survival. The present review will approach the rationale to re-shape the heart on the basis of pathophysiology and cardiac architecture, and will describe the efficacy of the Dor procedure in ischemic dilated cardiomyopathy, as well as some technical aspects and patient selection pathway. (Circ J 2009; Suppl A: A-1 – A-5) Key Words: Ischemic heart failure; Patient selection; Surgical ventricular restoration oronary artery disease in Western countries is respon- or have comorbidities that preclude transplantation; more- sible for more than 75% of heart failure (HF) over, the scarce number of donors makes the treatment C cases.1,2 Despite the improvement in the treatment unavailable for most patients on a waiting list.
    [Show full text]
  • (Dor Operation) in a Patient with Aortic Valve Stenosis and Severe Ischemic Cardiomyopathy
    Case Aortic Valve Replacement Combined with Endoventricular Circulatory Patch Plasty Report (Dor Operation) in a Patient with Aortic Valve Stenosis and Severe Ischemic Cardiomyopathy Kei Horiguchi, MD, Shigeaki Ohtake, MD, Goro Matsumiya, MD, Yoshiki Sawa, MD, Motonobu Nishimura, MD, Hisashi Satou, MD,* Nobuyoshi Kawai, MD, and Hikaru Matsuda, MD A 58-year-old woman with ischemic cardiomyopathy and aortic valve stenosis, underwent aortic valve replacement and simultaneous endoventricular circulatory patch plasty (Dor operation). She underwent coronary artery bypass grafting for severe triple vessel disease 10 years ago. Recently she started to show severe congestive heart failure. Aortic valve stenosis with a pressure gradient of 85-mmHg was also found. Coronary bypasses were all patent, but the left ventricle (LV) was severery dilated (LVDd/Ds=71/61 mm) and the ischemic car- diomyopathy was considered as the cause. She successfully underwent aortic valve replace- ment and endoventricular circulatory patch plasty. The initial postoperative course was complicated with intractable ventricular arrhythmia, but the subsequent course was smooth and the patient was discharged with improved symptoms (New York Heart Association, NYHA Class II). Postoperative catheterization showed decreased left ventricular volume and improved contractility. This case implies the role of LV remodeling procedure in the ischemic cardiomyopathy combined with aortic valve lesion. (Ann Thorac Cardiovasc Surg 2001; 7: 170–4) Key words: ischemic cardiomyopathy, endoventricular
    [Show full text]